banner
mTOR inhibitor OSI-027, Purity ≥98%
Inquiry

Cat. No.: X24-05-ZQ036

mTOR inhibitor OSI-027, Purity ≥98%

Synonym: 936890-98-1; OSI027; mTOR inhibitor

  • CAS Number: 936890-98-1
  • Compound CID: 135398516
img
Product Size
5 mg; 10 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
OSI-027, soluble in DMSO and insoluble in ethanol and water, disrupts cell growth, proliferation, and survival by targeting a key component of cellular signaling pathways. It targets mTORC1, mTORC2, ACK1, BTK, C-Raf, DNA-PK, EGFR/ErbB1, EphA2, Fyn, IGF-1R, and insulin receptor.
Molecular Weight
406.4
Molecular Formula
C21H22N6O3
Targets
mTORC1: 22 nM; mTORC2: 65 nM; ACK1: >10 μM; BTK: 5.0 μM; C-Raf: 1.6 μM; DNA-PK: 1.0 μM; EGFR/ErbB1: >30 μM; EphA2: 4.5 μM; Fyn: >30 μM; IGF-1R: >30 μM; InsulinReceptor: >30 μM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 16 mg/mL (39.36 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
OSI-027 can be employed to investigate dual mTORC1 and mTORC2 inhibition in oncology research.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0